Marinus Pharmaceuticals Future Growth

Future criteria checks 2/6

Marinus Pharmaceuticals is forecast to grow earnings and revenue by 61.9% and 34.7% per annum respectively while EPS is expected to grow by 69.3% per annum.

Key information

61.9%

Earnings growth rate

69.3%

EPS growth rate

Pharmaceuticals earnings growth	24.0%
Revenue growth rate	34.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	14 Nov 2024

Recent future growth updates

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11

Recent updates

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Sep 20

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Apr 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 08

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Dec 22

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Sep 22

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Jun 12

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

May 16

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Jul 28

Revisiting Marinus Pharmaceuticals

May 05

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03

Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption

Feb 28

Earnings and Revenue Growth Forecasts

NasdaqGM:MRNS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	72	-32	89	N/A	7
12/31/2025	55	-74	-87	N/A	9
12/31/2024	35	-114	-101	N/A	8
9/30/2024	31	-140	N/A	N/A	N/A
6/30/2024	30	-149	-121	-120	N/A
3/31/2024	28	-145	-114	-114	N/A
12/31/2023	31	-141	-118	-118	N/A
9/30/2023	31	-134	-113	-113	N/A
6/30/2023	26	-29	-119	-117	N/A
3/31/2023	22	-35	-128	-127	N/A
12/31/2022	25	-20	-115	-113	N/A
9/30/2022	20	-14	-115	-113	N/A
6/30/2022	28	-105	-80	-78	N/A
3/31/2022	28	-91	-69	-67	N/A
12/31/2021	15	-99	-58	-55	N/A
9/30/2021	15	-88	-52	-50	N/A
6/30/2021	5	-84	-71	-70	N/A
3/31/2021	4	-76	-63	-63	N/A
12/31/2020	2	-76	-61	-61	N/A
9/30/2020	0	-74	-61	-61	N/A
6/30/2020	N/A	-72	-58	-58	N/A
3/31/2020	N/A	-69	-51	-51	N/A
12/31/2019	N/A	-54	-49	-49	N/A
9/30/2019	N/A	-49	-42	-42	N/A
6/30/2019	N/A	-46	-37	-36	N/A
3/31/2019	N/A	-43	-34	-33	N/A
12/31/2018	N/A	-37	-28	-28	N/A
9/30/2018	N/A	-31	-23	-23	N/A
6/30/2018	N/A	-24	N/A	-19	N/A
3/31/2018	N/A	-19	N/A	-18	N/A
12/31/2017	N/A	-19	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-20	N/A
6/30/2017	N/A	-22	N/A	-24	N/A
3/31/2017	N/A	-27	N/A	-26	N/A
12/31/2016	N/A	-29	N/A	-25	N/A
9/30/2016	N/A	-30	N/A	-24	N/A
6/30/2016	N/A	-29	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-22	N/A
12/31/2015	N/A	-25	N/A	-20	N/A
9/30/2015	N/A	-21	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-14	N/A
3/31/2015	N/A	-17	N/A	-11	N/A
12/31/2014	N/A	-13	N/A	-9	N/A
9/30/2014	N/A	-12	N/A	-10	N/A
6/30/2014	N/A	-12	N/A	-8	N/A
3/31/2014	N/A	-11	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRNS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRNS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRNS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRNS's revenue (34.7% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: MRNS's revenue (34.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MRNS's Return on Equity is forecast to be high in 3 years time

Marinus Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024

Consensus EPS estimates upgraded to US$1.98 loss, revenue downgraded

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

Price target decreased by 49% to US$10.44

Recent updates

Marinus Pharmaceuticals Announces Topline Results from Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024

Marinus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Marinus Pharmaceuticals Announces Ganaxolone Approves in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Completeness Index

Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus

Robbins LLP Files A Class Action Against Marinus Pharmaceuticals, Inc

Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program

Consensus EPS estimates upgraded to US$1.98 loss, revenue downgraded

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Marinus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Price target decreased by 49% to US$10.44

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

New major risk - Share price stability

Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial

Marinus Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

CEO, President & Chairman exercised options to buy US$452k worth of stock.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Full year 2023 earnings: EPS and revenues miss analyst expectations

Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024

Marinus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

New major risk - Revenue and earnings growth

Marinus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.53 loss in 1Q 2022)

Price target decreased by 7.8% to US$22.60

New minor risk - Share price stability

Marinus Pharmaceuticals, Inc. Announces European Commission Approval of ZTALMY (Ganaxolone) Oral Suspension for Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder in Patients Two to 17 Years of Age

Marinus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Marinus Pharmaceuticals, Inc. Receives Positive CHMP Opinion for ZTALMY®? (ganaxolone) for the Adjunctive Treatment of Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. Appoints Sarah Noonberg as Member of the Board

Consensus revenue estimates increase by 11%

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: US$0.51 loss per share (vs US$2.69 loss in FY 2021)

Marinus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Marinus Pharmaceuticals, Inc. Appoints Steve Pfanstiel as Chief Operating Officer

Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Consensus forecasts updated

Marinus Pharmaceuticals, Inc. Announces Board Changes

Price target decreased to US$25.11

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Marinus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Consensus revenue estimates fall by 16%

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Marinus Pharmaceuticals: Positive News Flow Of Note

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Consensus revenue estimates increase by 59%

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY (Ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Marinus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022